Strattera Tapering: How to Stop Safely Without Rebound

Strattera (atomoxetine) discontinuation differs fundamentally from stopping many other psychiatric medications — it doesn't produce the physical withdrawal syndrome seen with SSRIs, SNRIs, benzodiazepines, or opioids, meaning Strattera can technically be stopped abruptly without dangerous medical consequences. However, "no physical withdrawal" doesn't mean "no tapering needed" — most prescribers recommend a gradual 4-week taper schedule rather than abrupt discontinuation, primarily to allow controlled ADHD symptom rebound (predictable return of ADHD symptoms as medication clears), to enable lifestyle and coping strategy implementation during transition, to facilitate possible switching to alternative ADHD medications, and to monitor for any mood changes (FDA Black Box for suicidal ideation remains relevant during medication changes). The standard tapering approach steps down through available capsule strengths — 100 mg → 80 mg → 60 mg → 40 mg → 0 — typically one week per step for a 4-week total taper. Faster tapers (2-week or even abrupt) are medically acceptable for specific situations; slower tapers (6-8 weeks) help patients with significant treatment sensitivity or mid-taper switching to alternative medications.

This guide provides comprehensive information about Strattera tapering for patients and prescribers managing planned discontinuation. We address whether Strattera actually needs tapering (the nuanced answer), the recommended standard weekly schedule, the specific 100→80→60→40→0 protocol with week-by-week guidance, when faster tapers are medically appropriate, ADHD symptom rebound timing and patterns to expect, considerations for switching to stimulant medications during taper, the considerations for re-starting Strattera later if needed, pre-taper preparation checklist for optimizing discontinuation success, rebound symptom tracker for objective monitoring, taper speed comparison framework, and the bottom-line framework for safely discontinuing this medication.

❓ Does Strattera Need Tapering

The nuanced answer to whether Strattera tapering is necessary:

• Pharmacologically: No physical withdrawal syndrome — Strattera can be stopped abruptly without dangerous medical consequences.
• Clinically: Tapering recommended for most patients despite no withdrawal.
• FDA labeling: Doesn't mandate tapering but practical guidance often suggests gradual discontinuation.
• Expert opinion: Most psychiatrists recommend tapering for better treatment transition.
• Patient experience: Smoother discontinuation with tapering than abrupt stop.

Strattera vs other psychiatric medications regarding discontinuation:

• SSRIs/SNRIs: Significant discontinuation syndrome — flu-like symptoms, dizziness, sensory disturbances, mood symptoms. Tapering essential.
• Benzodiazepines: Potentially dangerous withdrawal — seizures, autonomic instability. Slow tapering essential.
• Opioids: Significant physical withdrawal. Tapering or medical management essential.
• Stimulants (Adderall, Vyvanse): Limited physical withdrawal but ADHD symptoms return and depression-like fatigue common.
• Strattera: No physical withdrawal; only ADHD symptom rebound as drug clears.

Why we still taper despite no physical withdrawal:

• Gradual ADHD symptom return: Allows time to develop coping strategies and alternative supports.
• Mood monitoring: FDA Black Box warning for suicidal ideation remains relevant during medication changes.
• Facilitates switching: Easier to transition to alternative ADHD medication during taper.
• Patient psychological adjustment: Time to process treatment change.
• Lifestyle adjustment: Time to implement behavioral interventions, accommodations.
• Avoids dramatic functional decline: Sudden ADHD symptom return can significantly impact work/school.

When abrupt discontinuation is acceptable:

• Severe adverse reaction: Allergic reaction, hepatotoxicity, severe mood reaction — must stop immediately.
• Pregnancy discovery: Some prescribers prefer immediate cessation.
• Drug interaction emergency: If starting MAOI (absolute contraindication).
• Patient choice: Adult patient autonomy in their treatment decisions.
• Short treatment duration: Less than 2 weeks of treatment — minimal taper benefit.

Common patient misconception:

• "I have to taper Strattera like SSRIs." — False; physical withdrawal pattern different.
• "If I stop suddenly, I'll have terrible withdrawal." — False; ADHD symptoms return but no physical withdrawal.
• "Tapering is medically dangerous to skip." — False; medically safe to stop abruptly.
• Reality: Tapering preferred for practical/clinical reasons, not safety.

📅 Recommended Weekly Schedule

The standard 4-week tapering protocol:

• Step 1 (Week 1): Reduce from current dose by 20-25%.
• Step 2 (Week 2): Reduce by another 20-25%.
• Step 3 (Week 3): Reduce by another 20-25%.
• Step 4 (Week 4): Discontinue completely.
• Total duration: 4 weeks for most patients on standard doses.

Schedule based on starting dose:

If currently on 100 mg:

• Week 1: 80 mg daily.
• Week 2: 60 mg daily.
• Week 3: 40 mg daily.
• Week 4: 0 — discontinued.

If currently on 80 mg:

• Week 1: 60 mg daily.
• Week 2: 40 mg daily.
• Week 3: 18-25 mg daily.
• Week 4: 0 — discontinued.

If currently on 60 mg:

• Week 1: 40 mg daily.
• Week 2: 25 mg daily.
• Week 3: 10-18 mg daily.
• Week 4: 0 — discontinued.

If currently on 40 mg:

• Week 1: 25 mg daily.
• Week 2: 18 mg daily.
• Week 3: 10 mg daily.
• Week 4: 0 — discontinued.

Practical considerations during taper:

• Switch capsule strength weekly: Use available capsule strengths (10, 18, 25, 40, 60, 80, 100 mg).
• No need to alternate doses — clean weekly steps work.
• Continue same time of day: Don't change timing during taper.
• Same with food considerations: Don't change administration approach.
• Pharmacy coordination: Prescription for multiple capsule strengths.

Length of taper considerations:

• 4 weeks standard for most adults discontinuing.
• 2 weeks acceptable for shorter duration treatment or when needed quicker.
• 6-8 weeks slower for sensitive patients or coordinated medication switch.
• Abrupt (no taper) for emergencies or short-duration treatment.
• Pediatric tapers follow similar weight-based gradual reductions.

🪜 100mg → 80mg → 60mg → 40mg → 0 Standard Protocol

Detailed week-by-week of the standard 100→0 taper:

Week 1: 100 mg → 80 mg

• Day 1: Switch from 100 mg capsule to 80 mg capsule.
• Days 1-7: Continue 80 mg daily.
• What to expect: Subtle ADHD symptom changes; slight improvement in side effects.
• What to monitor: Mood, focus, daily functioning, side effects.
• Patient reports: Often "I feel about the same — maybe slightly more distractible."
• Cardiovascular changes: Slight decrease in heart rate, BP if monitoring.
• Day 7 assessment: Ready for next step? Plan tomorrow's reduction.

Week 2: 80 mg → 60 mg

• Day 1: Switch from 80 mg to 60 mg capsule.
• Days 1-7: Continue 60 mg daily.
• What to expect: More noticeable ADHD symptom return; side effects continuing to ease.
• What to monitor: Focus, impulsivity, executive function, mood.
• Patient reports: "I'm noticing I'm less focused" or "my attention isn't quite as sharp."
• Begin implementing supports: Behavioral strategies, organizational tools.
• Day 7 assessment: Continue plan or adjust based on functioning.

Week 3: 60 mg → 40 mg

• Day 1: Switch from 60 mg to 40 mg capsule.
• Days 1-7: Continue 40 mg daily.
• What to expect: ADHD symptoms more prominent; this is when many patients notice the change clearly.
• What to monitor: Daily functioning impact, mood, any concerning changes.
• Patient reports: "Things feel harder" or "I'm noticing my ADHD symptoms again."
• Plan for week 4: Alternative supports ready, possibly alternative medication starting.
• Day 7 assessment: Final week preparation; ensure supports in place.

Week 4: 40 mg → 0 (complete discontinuation)

• Day 1: No Strattera dose.
• Days 1-3: Last residual Strattera clearing from system.
• Days 4-14: Return to baseline ADHD symptoms (without medication).
• What to expect: Full ADHD baseline within 1-2 weeks; coping strategies essential.
• What to monitor: Significant functional decline, mood changes, ability to manage daily life.
• Day 14 assessment: Off-medication baseline established; assess need for alternatives.

Throughout taper monitoring:

• Daily symptom diary: ADHD symptoms, mood, side effects.
• Functional assessment: Work/school performance, daily tasks.
• Mood watch: FDA Black Box for suicidal ideation remains relevant.
• Side effect changes: Many improve as dose decreases.
• Sleep changes: Often improves as dose decreases.
• Appetite changes: May increase as medication decreases.
• Cardiovascular changes: BP/HR may decrease.

⚡ Faster Tapers: When OK

Situations where faster tapering is medically acceptable:

2-week accelerated taper:

• Schedule: 100 → 60 (week 1) → 0 (week 2). Or 80 → 40 → 0.
• Indications:
  • Need to discontinue quickly for medical reasons
  • Patient preference for faster discontinuation
  • Recent treatment initiation (less than 2 months on Strattera)
  • Starting alternative medication that needs Strattera cleared
• Considerations: ADHD symptom return more rapid; less time for supports implementation.

Abrupt discontinuation (no taper):

• Medically acceptable for:
  • Allergic reaction
  • Hepatotoxicity
  • Severe psychiatric reaction
  • Starting MAOI (absolute contraindication)
  • Pregnancy discovery (some clinicians' approach)
  • Short-duration treatment (<2 weeks)
• What to expect: ADHD symptoms return as medication clears (5-7 days for extensive metabolizers; longer for poor metabolizers).
• Cardiovascular changes: BP/HR return to baseline over days.
• Mood monitoring still important.

When abrupt discontinuation is medically indicated:

• Liver function abnormalities (jaundice, dark urine): Stop immediately; immediate medical evaluation.
• Severe allergic reaction (rash, swelling, breathing difficulty): Stop immediately; emergency care.
• Severe mood reaction (suicidal ideation): Stop or rapidly taper with close monitoring; immediate psychiatric care.
• Psychotic symptoms emerging: Stop immediately; psychiatric evaluation.
• Severe cardiovascular events: Stop immediately; medical management.
• Significant drug interaction: Stop immediately if contraindicated combination.

Patient choice considerations:

• Adult patient autonomy: Patients can choose faster taper or abrupt stop.
• Informed decision: Understand trade-offs (faster taper = more rapid ADHD symptom return).
• Prescriber recommendation: Usually 4 weeks but flexibility based on situation.
• Coordinate with life events: Schedule around work demands, school exams, important commitments.

Considerations for rapid taper:

• More dramatic ADHD symptom return: Greater functional impact short-term.
• Less time for support implementation.
• Mood monitoring still important.
• Re-evaluate quickly if significant functional decline.
• May restart if needed after assessment.

📈 ADHD Symptom Rebound Timing

Expected pattern of ADHD symptom return during taper:

Days 1-7 (during 80 mg phase):

• Subtle changes: Slight increase in distractibility.
• Functional impact: Minimal — most can compensate.
• Patient awareness: Often not yet noticed.
• Family/colleague observation: Subtle differences possibly noted.

Days 8-14 (during 60 mg phase):

• Noticeable changes: Attention, focus, working memory affected.
• Functional impact: Mild — strategies help compensate.
• Patient awareness: Usually noticed.
• Daily life: Task initiation harder, more reminders needed.

Days 15-21 (during 40 mg phase):

• Clear changes: ADHD symptoms back to about 50-70% of pre-medication.
• Functional impact: Moderate — coping strategies critical.
• Patient awareness: Clearly noticed.
• Decision point: Continue or reconsider?

Days 22-28 (post discontinuation week 1):

• Significant changes: Approaching baseline ADHD severity.
• Functional impact: Substantial — full coping arsenal needed.
• Patient awareness: Cannot ignore.
• Decision: Sustainable off-medication or need alternative?

Days 29-42 (post discontinuation week 2-3):

• Full ADHD baseline returned — pre-treatment level.
• True off-medication functional level established.
• Long-term plan needed: Behavioral interventions, alternative medication, or continue without medication.

Variations in rebound timing:

• CYP2D6 extensive metabolizers: Faster clearance; symptoms return faster.
• CYP2D6 poor metabolizers: Slower clearance; symptoms return slower (over 2-3 weeks).
• Concurrent CYP2D6 inhibitors: Drug-induced slow clearance.
• Length of treatment: Longer treatment may have more dramatic-feeling rebound.
• Individual variation: Wide range of experiences.

What ADHD rebound feels like:

• Attention difficulties: Easier distraction, harder sustained focus.
• Impulsivity: More impulsive decisions, interruptions.
• Executive function: Planning, organization, task initiation harder.
• Time management: Time blindness more pronounced.
• Working memory: Forgetting tasks, what was just discussed.
• Hyperactivity: Restlessness, fidgeting in those with hyperactive component.
• Emotional dysregulation: ADHD-related mood fluctuations.

What's NOT typical of Strattera rebound:

• Flu-like symptoms: Like SSRI discontinuation — not seen.
• Brain zaps: Like SSRI/SNRI — not seen.
• Dizziness, sensory disturbances: Like SSRI/SNRI — not seen.
• Seizures: Like benzodiazepine withdrawal — not seen.
• Autonomic dysregulation: Severe BP/HR changes — not seen.
• Cravings: Like opioid/stimulant withdrawal — not seen.

🔀 Switching to Stimulant Mid-Taper

Considerations when transitioning to stimulant ADHD medication:

Why switch mid-taper:

• Strattera ineffective: Want to try different mechanism.
• Significant side effects on Strattera.
• Insurance/cost considerations.
• Patient preference for stimulant.
• Want immediate-acting medication.

Common stimulant options:

• Methylphenidate-based: Concerta (long-acting), Ritalin (short-acting), Daytrana (patch), Quillivant XR (liquid).
• Amphetamine-based: Adderall (short and XR), Vyvanse (long-acting), Mydayis (very long-acting).
• Considerations: Schedule II controlled substances; different prescribing requirements.

Transition approach options:

Option 1 — Sequential approach (cleaner pharmacologically):

• Complete Strattera taper to 0.
• Wait 5-7 days for Strattera to fully clear.
• Start stimulant at standard starting dose.
• Titrate stimulant per usual protocol.
• Pros: Clear assessment of stimulant effect; no overlap confusion.
• Cons: 1-2 week unmedicated period.

Option 2 — Cross-taper (clinical bridging):

• Begin reducing Strattera while starting low-dose stimulant.
• Over 2-3 weeks, fully transition to stimulant.
• Pros: No unmedicated gap.
• Cons: Harder to assess which medication is doing what; more cardiovascular load briefly.

Option 3 — Overlap then discontinue:

• Start stimulant while continuing Strattera at reduced dose.
• Once stimulant effective, discontinue Strattera.
• Pros: Continuous ADHD treatment.
• Cons: Combined cardiovascular effects briefly; possible side effects of two medications.

Cardiovascular considerations during switching:

• Both medications increase BP/HR.
• Combined briefly: Some additional cardiovascular load.
• Monitor BP/HR during transition.
• Generally well-tolerated in patients without cardiovascular issues.
• Cardiology consultation if cardiovascular concerns.

Practical considerations:

• Schedule II prescribing: Stimulants require in-person evaluation generally.
• State regulations vary: Schedule II prescription rules.
• Insurance prior authorization: May be required.
• DEA scheduling considerations: Vs Strattera (not scheduled).
• Drug testing implications: Stimulants show on tests; Strattera doesn't.

🔄 Re-Starting Later

Considerations if needing to restart Strattera after discontinuation:

When restart might be considered:

• ADHD symptoms more impairing than expected off-medication.
• Alternative treatments didn't work or were intolerable.
• Life circumstances changed: New job, school program, increased demands.
• Mental health changes: Comorbid conditions emerging or worsening.
• Behavioral interventions insufficient alone.

Restart protocol:

• Same protocol as initial start: 40 mg starting → 80 mg target over 7 days.
• No need for longer/slower restart due to prior treatment.
• May tolerate faster: Some patients adapt faster on restart.
• Side effects similar to initial start: Nausea, fatigue, etc.
• Therapeutic effect timeline: Same 4-6 weeks to full effect.

Considerations for successful restart:

• Address reasons for original discontinuation: If side effects were issue, plan accordingly.
• Document prior trial: What dose worked, side effects experienced.
• Different dose considerations: Maybe lower target dose if poorly tolerated previously.
• Adjunctive strategies: Lifestyle, behavioral, cognitive interventions.
• Realistic expectations: Same medication, similar profile.

What might be different second time:

• Patient expectations refined: Knows what to expect.
• Better tolerance possibly: Body may adapt faster.
• Side effect awareness: Knows what's medication vs unrelated.
• Symptom recognition: Knows what therapeutic effect feels like.
• Coping skills developed: Off-medication period may have built skills now augmented by medication.

Multiple restarts considerations:

• Generally fine to restart multiple times — Strattera not abuse-liable.
• Pattern suggests reassessment: Multiple stops/starts may indicate fundamental treatment mismatch.
• Consider alternative medications if cycling.
• Address adherence issues if those drove stops.
• Comprehensive psychiatric review may help.

📋 Pre-Taper Preparation Checklist

Optimizing taper success through preparation:

1-2 weeks before starting taper:

• Discuss taper plan with prescriber — schedule, monitoring, follow-up.
• Get prescriptions for needed capsule strengths.
• Plan follow-up visits — typically week 4 and week 8.
• Inform close support people (family, partner, close friends).
• Plan timing around life events: Avoid major exams, work deadlines, life transitions during taper.
• Consider work/school accommodations during transition.

Document baseline before taper:

• Current ADHD symptom severity using validated scale (ASRS, CAARS).
• Current functional level: Work performance, daily tasks, relationships.
• Current side effects you experience.
• Current quality of life rating.
• BP and heart rate baseline.

Behavioral preparation:

• Identify ADHD coping strategies currently used vs medication-augmented.
• Strengthen organizational systems: Calendars, lists, reminders, structures.
• Sleep optimization: Good sleep amplifies non-medication ADHD management.
• Exercise routine establishment: Exercise improves ADHD symptoms.
• Nutrition optimization: Stable blood sugar helps focus.
• Stress management: Meditation, mindfulness, breathing techniques.

Alternative treatment planning (if applicable):

• Decision on next medication if any: Stimulant, alternative non-stimulant, no medication.
• Coordinate with new prescriber if changing.
• Therapy consideration: Cognitive behavioral therapy for ADHD.
• ADHD coaching: Specialized coaching for executive function.
• Support groups: Adult ADHD community.

Tracking preparation:

• Symptom tracker ready: Daily ratings during taper.
• Mood diary: FDA Black Box monitoring.
• Sleep tracker.
• Functional checklist: Daily tasks completion.
• App or paper journal: Whatever works for consistency.

Communication preparation:

• Tell partner/family: They can monitor and support.
• Tell close colleagues if appropriate: Understanding during transition.
• Tell prescriber clear communication channel: When to call vs email vs visit.
• Establish emergency contact: If concerning mood changes.

📊 Rebound Symptom Tracker

Objective rebound monitoring framework:

Daily rating scales (1-10):

• Attention/focus quality.
• Impulsivity level.
• Hyperactivity/restlessness.
• Executive function (task initiation, planning).
• Working memory.
• Mood (overall).
• Anxiety level.
• Sleep quality previous night.
• Energy level.
• Side effects severity.

Functional checklist:

• Started work on time.
• Completed planned daily tasks.
• Returned calls/emails appropriately.
• Maintained focus through meetings/classes.
• Followed through on commitments.
• Managed time effectively.
• Engaged appropriately in conversations.
• Made impulsive vs considered decisions.

Weekly summary questions:

• Compared to last week, am I functioning better, same, or worse?
• What specifically has changed?
• Are my coping strategies adequate?
• Am I able to maintain my work/school commitments?
• How are relationships going?
• Mood and mental health stable?
• Sleep, appetite, energy adequate?

Concerning patterns to report to prescriber:

• Significant functional decline: Can't keep up with work/school despite efforts.
• Mood changes: Sadness, anxiety, irritability beyond expected ADHD-related emotional changes.
• Suicidal thoughts: ANY expression warrants immediate contact (FDA Black Box).
• Severe ADHD symptom return: Worse than pre-medication baseline.
• Relationship strain: Significantly affecting relationships.
• Self-medication temptation: Considering substances or other coping.

Decision points during tracking:

• Continue taper as planned if functioning acceptable.
• Slow taper if difficulty managing symptoms.
• Pause taper if significant functional decline.
• Reverse taper if not sustainable off-medication.
• Accelerate alternative treatment start if planned.

⚖️ Taper Speed Comparison

Four taper speed approaches:

Slow taper (6-8 weeks). Used for: very sensitive patients, coordinated medication switching, history of difficult psychiatric medication changes, patient preference. Schedule example from 100 mg: 80 mg (weeks 1-2), 60 mg (weeks 3-4), 40 mg (weeks 5-6), 25 mg (weeks 7-8), 0. Pros: most gradual ADHD symptom return; maximum time for support implementation. Cons: longer duration; some patients find prolonged tapering psychologically difficult.

Standard taper (4 weeks). Used for: most adult patients, standard discontinuation, typical clinical practice. Schedule: 100→80→60→40→0 over 4 weeks. Pros: balanced approach; manageable timeframe; gradual symptom return; standard practice. Cons: ADHD symptoms more noticeable than slow taper.

Fast taper (2 weeks). Used for: shorter treatment duration, need to discontinue quickly, transition to alternative medication, patient preference for quicker discontinuation. Schedule examples: 100→50→0 over 2 weeks, or 80→40→0 over 2 weeks. Pros: faster transition; quicker assessment of off-medication state. Cons: more rapid ADHD symptom return; less time for support implementation.

Abrupt discontinuation. Used for: medical emergencies (allergic reaction, hepatotoxicity, severe psychiatric reaction), starting MAOI (contraindication), pregnancy discovery (some clinicians), short treatment duration (less than 2 weeks). Schedule: stop immediately. Pros: no taper period; immediate medical safety in urgent situations. Cons: dramatic ADHD symptom return; sometimes mood implications.

✨ Bottom Line

Strattera tapering differs from many psychiatric medication discontinuations — no physical withdrawal syndrome, but tapering still preferred for managing ADHD symptom rebound, mood monitoring, facilitating treatment transitions, and psychological adjustment. The Taper Ladder Roadmap establishes the standard 4-week protocol: 100→80→60→40→0 with one week per step. Total duration 4 weeks; faster (2 weeks) or slower (6-8 weeks) options available for specific situations.

Does Strattera need tapering? Pharmacologically no (no physical withdrawal), clinically yes for most patients (better treatment transition). Strattera differs from SSRIs/SNRIs (no discontinuation syndrome), benzodiazepines (no dangerous withdrawal), opioids (no physical dependence). Tapering still recommended for: gradual ADHD symptom return management, mood monitoring (FDA Black Box for suicidal ideation remains relevant), facilitating alternative medication switching, patient psychological adjustment, lifestyle adjustment, avoiding dramatic functional decline.

The Standard Weekly Schedule reduces dose by 20-25% weekly. Specific protocols based on starting dose: 100 mg → 80→60→40→0; 80 mg → 60→40→18-25→0; 60 mg → 40→25→10-18→0; 40 mg → 25→18→10→0. Switch capsule strength weekly using available 10, 18, 25, 40, 60, 80, 100 mg strengths.

The 100→80→60→40→0 standard protocol week-by-week guidance: Week 1 (100→80) subtle changes; Week 2 (80→60) more noticeable; Week 3 (60→40) clearly noticed; Week 4 (40→0) full discontinuation; Days 29-42 full ADHD baseline returned. Throughout monitor: daily symptom diary, functional assessment, mood watch, side effect changes, sleep, appetite, cardiovascular.

The Taper Goal — not to avoid physical withdrawal but to manage predictable ADHD symptom return gradually. Provides time to assess "how much does Strattera actually help me?" and implement supports. Many patients realize either "I really need this" (may resume) or "I was managing better than I thought" (successful discontinuation).

Faster tapers acceptable: 2-week accelerated for shorter treatment or transition; abrupt discontinuation for medical emergencies (allergic reaction, hepatotoxicity, severe psychiatric reaction, starting MAOI, pregnancy discovery, short treatment duration). Cardiovascular changes return to baseline over days; mood monitoring still important.

ADHD symptom rebound timing: Days 1-7 subtle changes; Days 8-14 noticeable; Days 15-21 clear; Days 22-28 significant; Days 29-42 full baseline. Variations by CYP2D6 phenotype (extensive metabolizers faster return; poor metabolizers slower). What's typical: attention difficulties, impulsivity, executive function issues, time blindness, working memory deficits, possible hyperactivity, emotional dysregulation. What's NOT typical: flu-like symptoms, brain zaps, dizziness/sensory disturbances, seizures, autonomic dysregulation, cravings.

Switching to stimulant mid-taper options: Sequential (complete Strattera taper, wait 5-7 days, start stimulant — cleanest); Cross-taper (begin stimulant while reducing Strattera over 2-3 weeks — no unmedicated gap); Overlap (start stimulant on reduced Strattera, then discontinue — continuous treatment). Schedule II prescribing considerations, cardiovascular monitoring during transition, insurance prior authorization may be needed.

Re-starting later if needed uses same protocol as initial start (40→80 mg over 7 days). No need for slower restart due to prior treatment. May tolerate faster. Therapeutic timeline same 4-6 weeks. Document prior trial. Multiple restarts generally fine but pattern suggests reassessment.

Pre-taper preparation checklist 1-2 weeks before: discuss plan with prescriber, get prescriptions, plan follow-ups, inform support people, schedule around life events. Document baseline (ADHD scale, functional level, side effects, quality of life, BP/HR). Behavioral preparation (coping strategies, organizational systems, sleep, exercise, nutrition, stress management). Alternative treatment planning. Tracking preparation. Communication preparation.

Rebound Symptom Tracker uses daily 1-10 rating scales (attention, impulsivity, hyperactivity, executive function, working memory, mood, anxiety, sleep, energy, side effects), functional checklist, weekly summary questions, concerning patterns to report (significant functional decline, mood changes, suicidal thoughts, severe symptom return, relationship strain, self-medication temptation).

The Taper Speed Comparison: Slow (6-8 weeks for sensitive patients/complex switching), Standard (4 weeks default for most), Fast (2 weeks for quick discontinuation needed), Abrupt (0 — medical emergencies only). Match taper speed to individual circumstances rather than one-size-fits-all approach.

The fundamental discontinuation principle: Strattera can be stopped safely; gradual tapering improves the transition experience. Realistic expectations about ADHD symptom return prevent disappointment. Backup plans for ADHD management (alternative medications, behavioral interventions, lifestyle optimization) enable successful long-term outcomes whether continuing off-medication or finding alternative treatments.

For broader Strattera context and complementary topics, see Strattera Starting Dose for Adults, Strattera 80mg vs 100mg, Strattera Dose for Children and Teens, Strattera Once vs Twice Daily, Strattera Withdrawal and Discontinuation (related deeper coverage), Strattera and Alcohol, Strattera and Caffeine, Strattera and SSRI/SNRI, Strattera and MAOIs (washout consideration if switching), Strattera and Birth Control, Strattera and Marijuana, Strattera and Antihistamines, Strattera and Albuterol, Cardiovascular Effects, Liver Health, FDA Black Box SI (critical for taper monitoring), Sleep Effects, Long-Term Side Effects, Weight Loss, and Sexual Side Effects.

For Strattera comparison cluster (when considering alternatives post-taper): vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree.

For modafinil as alternative ADHD treatment post-Strattera-discontinuation, Modalert 200 mg from Sun Pharma provides Schedule IV option.

❓ Frequently Asked Questions

📚 References & Further Reading

• FDA prescribing information for Strattera (atomoxetine) — discontinuation considerations.
• American Academy of Family Physicians — ADHD treatment discontinuation guidelines.
• American Psychiatric Association — psychiatric medication discontinuation principles.
• Clinical Pharmacogenetics Implementation Consortium — CYP2D6 atomoxetine pharmacokinetics.
• National Institute of Mental Health — ADHD treatment guidance.
• Adult ADHD organizations — patient resources for treatment transitions.
• Pharmacology literature — atomoxetine half-life and clearance data.
• Strattera dosing protocol cluster: Adult Starting Dose, 80mg vs 100mg, Pediatric Dose, Once vs Twice Daily
• Strattera lifestyle/interaction cluster: Alcohol, Caffeine, SSRI/SNRI, MAOIs, Birth Control, Marijuana, Antihistamines, Albuterol
• Strattera safety cluster: Long-Term, Cardiovascular, Liver Health, FDA Black Box SI, Sleep, Weight Loss, Sexual Side Effects, Withdrawal
• Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree
• Modalert 200 mg, Modvigil 200 mg, Waklert 150 mg — primary product pages.
• RXshop Editorial Team — content reviewed by licensed pharmacist; for adult patient education, not a substitute for individual medical consultation.